IT'S ABOUT TIME. - Dako

ABSTRACT BOOKECP 2012 24th European Congress of PathologySeptember 8 – 12, 2012 I Prague Congress Centre, Czech RepublicThree HoursThirty MinutesIT’S ABOUT TIME.HER2 IQFISH pharmDx Get Your In Situ HybridizationResults in 3½ Hours – InstantlyImprove Your Patient Care

Dako Scientific SymposiumMonday, September 10 | 12:45 – 14:15Prague Congress Centre | North HallProgram12:30 - 12:45 Lunch will be served before the meeting12:45 - 12:50 Welcome and IntroductionBy Prof. Giuseppe Viale, MD, FRCPath, European Institute ofOncology and University of Milan, ItalyPerformance Evaluation – Results from Clinical Pathology Laboratories in Europe12:50 - 13:10 Intra-laboratory Comparison StudyBy Prof. Josef Rüschoff, Chief Medical Officer of targosmolecular pathology gmbh, Kassel, Germany13:10 - 13:30 Inter-laboratory Comparison Study Involving Five FrenchBreast Cancer InstitutionsBy Dr. Magali Lacroix-Triki, MD, Institut Claudius Regaud, Toulouse, France13:30 - 13:50 Inter-laboratory Comparison Study Involving Three SpanishBreast Cancer InstitutionsBy Dr. David Hardisson, University Hospital La Paz, School of Medicine,Autonomous University of Madrid, IdiPAZ, Madrid, SpainClinical Perspectives13:50 - 14:10 How Will This New Technology Change the Use of ISH and Breast CancerDiagnostics and the Values for the Oncologist and PatientsBy Prof. Giuseppe Viale, MD, FRCPath, European Institute ofOncology and University of Milan, Italy14:10 - 14:15 Discussion and ClosingBy Prof. Giuseppe Viale, MD, FRCPath, European Institute ofOncology and University of Milan, ItalyECP2012

Dako Scientific Symposium | HER2 IQFISH pharmDx - Get Your In Situ Hybridization Results in 3½ Hours– Instantly Improve Your Patient CareHER2 IQFISH pharmDxGet Your In Situ Hybridization Results in 3½ Hours– Instantly Improve Your Patient CareModeratorCV | Professor Giuseppe Viale, MD, FRCPath, EuropeanInstitute of Oncology and University of Milan, ItalyProf. Viale was born in Torino (Italy) on June 23, 1952 and graduated from University of Milan in 1976.He became a specialist in pathology in 1979, and is now full professor of Pathology at the University ofMilan, School of Medicine. He has been director of the Division of Pathology and Laboratory Medicine atthe IEO since 1994, and deputy Scientific Director since 2010. Previously, he was assistant pathologist atS. Raffaele Hospital, Milan (1978-1981), and vice-director of Department of Pathology S. Paolo Hospital,Milan (1981-1994). A member from 1987, he was elected Fellow of the Royal College of Pathologistsin 1997. Scientific interests include abnormal expression of oncogenes and tumour suppressor genesin human malignancies, derangements in cell-cycle control and apoptotic pathways, and the role ofangiogenesis in tumour progression and response to therapy.He is active member of many international societies, organizations and committees such as the AJCCworking group for the TNM classification of breast cancer, Pathology Sub-study Group of the IntergroupExemestane Study (PathIES), Executive and Steering Committees of the Aphinity trial and responsiblefor the Central Pathology Laboratory, FFPE Working Group of the Breast International (BIG) and NationalCancer Institute (NCI)-sponsored breast cancer Cooperative Groups, Early Breast Cancer Trialists’Collaborative Group Steering Committee, Founding Member of the International Sentinel Node Society,Co-chair of the Translational Research Committee of the BIG2-98 trial (Trans-TAX), Executive and SteeringCommittees of the Breast International Group (BIG) and of the MINDACT trial, Translational ResearchCommittee of the HERA trial, Scientific/Translational Research Committee of the Breast InternationalGroup (BIG), Scientific Committee of the Italian National Institute of Health, co-chairman of the CentralPathology Office of the International Breast Cancer Study Group (IBCSG) and the Scientific Committeeof the International Breast Cancer Study Group (IBCSG). Prof. Viale has authored 390 articles in indexedinternational Journals and 36 chapters in books.

Dako Scientific Symposium | HER2 IQFISH pharmDx - Get Your In Situ Hybridization Results in 3½ Hours– Instantly Improve Your Patient CarePerformance - Inter-laboratory Comparison StudyInvolving Five French Breast Cancer InstitutionsCV | Dr. Magali Lacroix-Triki, MD, Institut ClaudiusRegaud, Toulouse, FranceBorn in Paris in 1971, Dr. M. Lacroix-Triki graduated in Pathology in Toulouse in 2001. Specializedin Breast Pathology, she works as a full-time pathologist at Claudius Regaud Institute, aComprehensive Cancer Center which is planned to become a major part of the new ToulouseCancer Campus (Oncopôle) in 2013. Author of 34 original papers, she is now completing her PhDon post-transcriptional regulation of gene expression in breast cancer and has written severalbook chapters in Breast Pathology in collaboration with Prof. J. Reis-Filho (Editors J. Palazzo andD. Dabbs). In 2009-2010, she held a Research Fellow position in Prof. J. Reis-Filho’s MolecularPathology Lab (Breakthrough Breast Cancer Research Centre, Institute of Cancer Research,London, UK), where she conducted several translational research studies on breast cancer.President of the French GEFPICS group (a national group composed of pathologists working onbreast cancer biomarkers) since 2011, she is also the Referent Pathologist of several UNICANCERclinical trials such as the Tavix/PACS08 (including 800 patients with triple-negative tumors),SAFIR-01, GERICO11/PACS10, or UNIRAD. She chairs the TRANSPACS08 steering committeeand is an active pathologist in several Scientific Committees of UNICANCER clinical trials whichare dedicated to translational research in breast cancer. Her research interests are mainly posttranscriptionalregulation of gene expression in breast cancer and translation regulation by thePI3K/Akt/mTOR pathway in collaboration with a research team from Gustave Roussy Institute,Villejuif, France (Dr S. Vagner, Prof. F. André). She is member of USCAP, SFSPM and of the ScientificBoard of the French Quality Assurance Program (AFAQAP).

Dako Scientific Symposium | HER2 IQFISH pharmDx - Get Your In Situ Hybridization Results in 3½ Hours– Instantly Improve Your Patient CarePerformance - Inter-laboratory Comparison StudyInvolving Three Spanish Breast Cancer InstitutionsCV | Dr. David Hardisson, University Hospital La Paz,School of Medicine, Autonomous University of Madrid,IdiPAZ, Madrid, SpainDr. David Hardisson obtained his M.D. and Ph.D. degrees from the University of Oviedo, Spain. Heattended the residence in Anatomic Pathology at the University Hospital La Paz in Madrid, wherehe now serves as responsible of the Breast and Gynecologic Pathology Section. From 2001 to 2008he was Assistant Professor of Pathology at the Autonomous University of Madrid, and since 2008he was appointed as an Associated Professor of Pathology at the same University, where he iscurrently the Director of the Department of Pathology.Dr. Hardisson is member of the Spanish Society of Pathology, European Society of Pathologyand USCAP. His research interests are primarily focused on the molecular basis of breast andgynecologic cancer, and he is the Director of the research group of Breast and GynecologicCancer at the Hospital La Paz Institute for Health Research (IdiPAZ). He has authored over 90 peerreviewedpapers and participated, as invited speaker, at many national and international coursesand congresses.ECP2012

Dako Scientific Symposium | HER2 IQFISH pharmDx - Get Your In Situ Hybridization Results in 3½ Hours– Instantly Improve Your Patient CareHow Will This New Technology Change the Useof ISH and Breast Cancer Diagnostics and theValues for the Oncologist and Patients?CV | Professor Giuseppe Viale, MD, FRCPath, EuropeanInstitute of Oncology and University of Milan, ItalyProf. Viale was born in Torino (Italy) on June 23, 1952 and graduated from University of Milan in 1976.He became a specialist in pathology in 1979, and is now full professor of Pathology at the University ofMilan, School of Medicine. He has been director of the Division of Pathology and Laboratory Medicine atthe IEO since 1994, and deputy Scientific Director since 2010. Previously, he was assistant pathologist atS. Raffaele Hospital, Milan (1978-1981), and vice-director of Department of Pathology S. Paolo Hospital,Milan (1981-1994). A member from 1987, he was elected Fellow of the Royal College of Pathologistsin 1997. Scientific interests include abnormal expression of oncogenes and tumour suppressor genesin human malignancies, derangements in cell-cycle control and apoptotic pathways, and the role ofangiogenesis in tumour progression and response to therapy.He is active member of many international societies, organizations and committees such as the AJCCworking group for the TNM classification of breast cancer, Pathology Sub-study Group of the IntergroupExemestane Study (PathIES), Executive and Steering Committees of the Aphinity trial and responsiblefor the Central Pathology Laboratory, FFPE Working Group of the Breast International (BIG) and NationalCancer Institute (NCI)-sponsored breast cancer Cooperative Groups, Early Breast Cancer Trialists’Collaborative Group Steering Committee, Founding Member of the International Sentinel Node Society,Co-chair of the Translational Research Committee of the BIG2-98 trial (Trans-TAX), Executive and SteeringCommittees of the Breast International Group (BIG) and of the MINDACT trial, Translational ResearchCommittee of the HERA trial, Scientific/Translational Research Committee of the Breast InternationalGroup (BIG), Scientific Committee of the Italian National Institute of Health, co-chairman of the CentralPathology Office of the International Breast Cancer Study Group (IBCSG) and the Scientific Committeeof the International Breast Cancer Study Group (IBCSG). Prof. Viale has authored 390 articles in indexedinternational Journals and 36 chapters in books.

Corporate HeadquartersDenmark+45 44 85 95 00www.dako.comRepresented in morethan 80 countriesAustralia+61 3 9357 0892Austria+43 1 408 43 34 0Belgium+32 (0) 16 38 72 20Brazil+55 11 50708300Canada+1 905 335 3256China+86 21 6327 1122Denmark+45 44 85 97 56Finland+358 9 348 73 950France+33 1 30 50 00 50Germany+49 40 69 69 470Ireland+353 1 479 0568Italy+39 02 58 078 1Japan+81 3 5802 7211The Netherlands+31 20 42 11 100Norway+47 23 14 05 40Poland+48 58 661 1879Spain+34 93 499 05 06Sweden+46 8 556 20 600Switzerland+41 41 760 11 66United Kingdom+44 (0)1 353 66 99 11United States of America+1 805 566 665550116 26JUN12